Roche: positive phase III results for influenza treatment
(CercleFinance.com) - Roche said a late-stage study showed its investigational oral baloxavir significantly reduced the time to improvement of influenza symptoms versus placebo in people at high risk of serious complications from flu, which includes adults of 65 years and above.
A phase III study showed treatment with baloxavir marboxil's median time to improvement of influenza symptoms was 73.2 hours versus 102.3 hours for placebo.
Participants were people at high risk of serious complications from the flu, including adults of 65 years old and above, or those who have conditions such as asthma, chronic lung disease, morbid obesity, or heart disease.
The study's results will be presented as a late-breaking oral presentation during IDWeek 2018 in San Francisco this Saturday 6 October.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
A phase III study showed treatment with baloxavir marboxil's median time to improvement of influenza symptoms was 73.2 hours versus 102.3 hours for placebo.
Participants were people at high risk of serious complications from the flu, including adults of 65 years old and above, or those who have conditions such as asthma, chronic lung disease, morbid obesity, or heart disease.
The study's results will be presented as a late-breaking oral presentation during IDWeek 2018 in San Francisco this Saturday 6 October.
Copyright (c) 2018 CercleFinance.com. All rights reserved.